Methadone in Post-Herpetic Neuralgia Pain

Phase 3

Completed

• Conditions: Post-herpetic Neuralgia
• Interventions: Drug: Methadone; Drug: Placebo

• Registration Number: NCT01752699
• Lead Sponsor: University of Sao Paulo

Brief Summary

Neuropathic pain is a common condition and affecting 40 to 70% of the general population. Post-herpetic neuralgia is a condition almost complex and requires a multi modal treatment. Aim: This is a pilot proof-of-principle study designed to evaluate the use of low-dose methadone in post-herpetic neuralgia patients who remained refractory after first and second line treatment for post-herpetic neuralgia (PHN) and had indication for the association of an opioid agent to their current drug regimen.

Detailed Description

Not available

Study Timeline

• Study Start: 1998-01
• Study First Submitted: 2012-12-11
• Study First Submitted QC: 2012-12-14
• Study First Posted: 2012-12-19
• Primary Completion: 2013-02
• Status Verified: 2013-03
• Study Completion: 2013-03
• Last Update Submitted: 2013-03-14
• Last Update Posted: 2013-03-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• Patients with chronic (>6 months) symptomatic PHN
• with visual analogical scale >40/100mm
• use of first and second line drugs (tricyclic antidepressants, venlafaxine and gabapentinoids)

Exclusion Criteria

• Don't full the criteria above

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Methadone	Methadone	in this arm patients will take methadone 5mg.
Placebo	Placebo	in this arm patients will take placebo pills.

Primary Outcome Measures

Name	Time	Method
Change in baseline Pain	baseline (visit inclusion) and three moths latter	Assessing by verbal analog scale (VAS)